Statements Solange Peters & Alessandra Curioni-Fontecedro (Highlights)
(The statements will be uploaded later in the day and week)
Papers mentioned:
NEJM: M.D. Hellmann and Others: Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Rolf Stahel, et al.
 |
POSTER |
Conclusions
Our analysis provides further evidence of the importance of the volume of experience and the availability of a multidisciplinary organisation and research environment, as delivered by a comprehensive cancer centre, on the outcome of patients with all stages of NSCLC.
Head & Neck Cancer
- 1118PD Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): safety phase of randomized trial GORTEC 2017-01 (REACH)
Conclusions: The combination of avelumab, cetuximab and RT is tolerable for pts with LA-SCCHN in the safety phase of this ongoing phase 3 trial and an approval to continue the trial was given by IDSMC.